TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25733335

Group type: EXPERIMENTAL
Intervention: Revised major purgative decoction (100 ml infused through the decompression tube, three times daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neostigmine (0.5 mg by muscle injection, twice daily)
Number of subjects: 31
Study: 24667866

Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion (30% soybean oil, 30% medium-chain triacylglycerol, 25% olive oil, 15% fish oil)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pure soybean oil emulsion (control)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Multicomponent lipid emulsion and Pure soybean oil emulsion
Number of subjects: 96
Study: 22017727

Group type: EXPERIMENTAL
Intervention: Neck-worn device that offers vibration when in supine position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neck-worn device in ON modus
Number of subjects: 30
Study: 19262464

Group type: EXPERIMENTAL
Intervention: Refill adherence <40%
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Prescription label reading skills
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adequate health literacy
Number of subjects: 192
Study: 17467237

Group type: EXPERIMENTAL
Intervention: Novalac-IT
Number of subjects: 93

Group type: COMPARATOR
Intervention: 20% strengthened formula (S group)
Number of subjects: 93
Study: 16138563

Group type: EXPERIMENTAL
Intervention: Combination of angiotensin receptor blockers, beta-blockers, or thiazide diuretics in addition to benidipine hydrochloride with response-dependent dose titration
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3000
Study: 12466030

Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/d
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9642886

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) training
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Supportive-expressive dynamic therapy (SE) training
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Individual drug counseling training
Number of subjects: 202

Group type: COMPARATOR
Intervention: Drug counseling training
Number of subjects: 202
Study: 9545905

Group type: EXPERIMENTAL
Intervention: Experimental resin-modified glass ionomer cement (K-512 = Fuji III LC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Light-cured resin-based sealant (Delton Opaque)
Number of subjects: 17
Study: 2021339

Group type: EXPERIMENTAL
Intervention: Level I axillary involvement
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Level II axillary involvement
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Level III axillary involvement
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Total number of positive nodes (one to three)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Total number of positive nodes (four or more)
Number of subjects: 135
Study: 6759139

Group type: EXPERIMENTAL
Intervention: 300 mg carprofen daily in 3 doses for 21 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: 150 mg diclofenac-Na daily in 3 doses for 21 days
Number of subjects: 50
Study: 31435005

Group type: EXPERIMENTAL
Intervention: Increased urinary phosphorus excretion
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Added phosphorus intake
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Total phosphorus intake
Number of subjects: 622
Study: 30554434

Group type: EXPERIMENTAL
Intervention: Self-assessment of handwritten prescriptions
Number of subjects: 580

Group type: COMPARATOR
Intervention: External assessment of handwritten prescriptions
Number of subjects: 580
Study: 27765610

Group type: EXPERIMENTAL
Intervention: tPCS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of tPCS and tDCS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study: 26074314

Group type: EXPERIMENTAL
Intervention: EPA 1.8 g/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DHA 1.8 g/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Olive oil 6.0 g/day
Number of subjects: 50
Study: 23710688

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day (bulimic patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day (non-bulimic patients)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 21481486

Group type: EXPERIMENTAL
Intervention: EBUS
Number of subjects: 264

Group type: COMPARATOR
Intervention: Non-EBUS
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Biopsy and brushing
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Brushing added to biopsy
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Washing or TBNA
Number of subjects: 264
Study: 19224481

Group type: EXPERIMENTAL
Intervention: Active antigen stimulation (low concentration 1:100 and high concentration 1:40)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 17205469

Group type: COMPARATOR
Intervention: Standard melarsoprol therapy (3 series of 3.6 mg/kg/day iv for 3 days, with 7-day breaks between series)
Number of subjects: 278

Group type: COMPARATOR
Intervention: 10-day incremental-dose melarsoprol therapy (0.6 mg/kg iv on day 1, 1.2 mg/kg iv on day 2, and 1.8 mg/kg iv on days 3-10)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Nifurtimox monotherapy for 14 days (5 mg/kg orally 3 times per day)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Consecutive 10-day melarsoprol-nifurtimox combination therapy (0.6 mg/kg iv melarsoprol on day 1, 1.2 mg/kg iv melarsoprol on day 2, and 1.2 mg/kg/day iv melarsoprol combined with oral 7.5 mg/kg nifurtimox twice a day on days 3-10)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: All regimens (including monotherapy)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 278
Study: 14997270

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (40-60% HRR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Light intensity exercise (10-20% HRR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 84
Study: 11249916

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study: 9609370

Group type: EXPERIMENTAL
Intervention: xenogenic bovine bone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: demineralized freeze-dried bone (DFDBA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: human bone morphogenetic proteins in an osteocalcein/osteonectin carrier (hBMP/NCP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: micro screws with bovine bone
Number of subjects: 8

Group type: COMPARATOR
Intervention: micro screws with DFDBA
Number of subjects: 8

Group type: COMPARATOR
Intervention: micro screw with intra-oral autologous bone
Number of subjects: 8
Study: 7663574

Group type: EXPERIMENTAL
Intervention: Wobenzym (WE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study: 2646258

Group type: EXPERIMENTAL
Intervention: Conventional preoperative radiotherapy (5000 cGy/25 Fx/5 wk) with hyperthermia (HT) given once or twice weekly during the 5 week course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Requiring ≥ 1/3 of treatments to satisfy the discriminant equation
Number of subjects: 0
Study: 237519

Group type: EXPERIMENTAL
Intervention: Medazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dummy capsule (placebo)
Number of subjects: 0
Study: 30656889

Group type: EXPERIMENTAL
Intervention: Precise hepatectomy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional hepatectomy
Number of subjects: 116
Study: 27862806

Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance (FG)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Combined guidance (CG)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Total ultrasonographic guidance (USG)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study: 25361657

Group type: EXPERIMENTAL
Intervention: Otilonium bromide (spasmolytic)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no spasmolytic)
Number of subjects: 100
Study: 23887198

Group type: EXPERIMENTAL
Intervention: Lidocaine patch (5%)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline intraepidermal nerve fiber density
Number of subjects: 21
Study: 21981451

Group type: COMPARATOR
Intervention: Control condition of continuous postocclusion hyperaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 seconds of reactive hyperaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 seconds of reactive hyperaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 seconds of reactive hyperaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 seconds of reactive hyperaemia (second cuff release)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 seconds of reactive hyperaemia (second cuff release)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 seconds of reactive hyperaemia (second cuff release)
Number of subjects: 10
Study: 18482418

Group type: EXPERIMENTAL
Intervention: naltrexone (50 mg/day)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: acamprosate (1998 mg/day)
Number of subjects: 169

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study: 16528138

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg/day)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 323
Study: 14567887

Group type: COMPARATOR
Intervention: Cetrorelix (GnRH antagonist) 3 mg
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Decapeptyl Retard (GnRH agonist) 3.75 mg
Number of subjects: 671
Study: 10877165

Group type: EXPERIMENTAL
Intervention: Td-IPV
Number of subjects: 301

Group type: COMPARATOR
Intervention: Td
Number of subjects: 301
Study: 9351406

Group type: EXPERIMENTAL
Intervention: Hemofer (27 mg elemental iron with heme and non-heme iron)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Collets jern med vitamin C (27 mg elemental iron with non-heme iron)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 7692166

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 0
Study: 3549869

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150-300 mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Desipramine (150-300 mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low-dose desipramine (50 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low-dose amitriptyline (50 mg)
Number of subjects: 99
Study: 31015198

Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29486131

Group type: EXPERIMENTAL
Intervention: AEE (Agrimonia eupatoria L. aqueous extract) - 2 capsules twice a day for 8 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo - 2 capsules twice a day for 8 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: AEE (Agrimonia eupatoria L. aqueous extract)
Number of subjects: 69
Study: 26747264

Group type: EXPERIMENTAL
Intervention: Double reading with consensus and arbitration
Number of subjects: 57157

Group type: COMPARATOR
Intervention: Single reading with first reader only
Number of subjects: 57157
Study: 24655407

Group type: EXPERIMENTAL
Intervention: ω-3 fish oil fat emulsion-based parenteral nutrition
Number of subjects: 48

Group type: COMPARATOR
Intervention: Soybean oil (Control)
Number of subjects: 48
Study: 22001664

Group type: EXPERIMENTAL
Intervention: Warning with the word 'sting'
Number of subjects: 100

Group type: COMPARATOR
Intervention: Warning with the word 'beware'
Number of subjects: 100
Study: 20823345

Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control subjects (euthyroid)
Number of subjects: 45
Study: 17372696

Group type: EXPERIMENTAL
Intervention: Indium chloride adsorbed onto activated charcoal, entrapped in cellulose acetate polymer melt; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 15783255

Group type: EXPERIMENTAL
Intervention: Antifibrinolytic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12063705

Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 50
Study: 9466024

Group type: EXPERIMENTAL
Intervention: 3-in-1 femoral nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 40
Study: 7893018

Group type: EXPERIMENTAL
Intervention: High infusion (20 mL/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low infusion (2 mL/kg)
Number of subjects: 200
Study: 2761685

Group type: EXPERIMENTAL
Intervention: 40 mg hydrocortisone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29304768

Group type: EXPERIMENTAL
Intervention: Long-lasting vaginal Lactobacillus rhamnosus BMX 54 administration (6 months)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Short-term vaginal Lactobacillus implementation (3 months)
Number of subjects: 117
Study: 27076041

Group type: EXPERIMENTAL
Intervention: Adjuvant interferon α‐2b (IFN)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 602

Group type: COMPARATOR
Intervention: High YKL‐40 expression in macrophages in lymph node metastases
Number of subjects: 602

Group type: COMPARATOR
Intervention: Increases in YKL‐40 during follow-up
Number of subjects: 602
Study: 25659520

Group type: EXPERIMENTAL
Intervention: 30 mg rectal morphine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22949583

Group type: EXPERIMENTAL
Intervention: Genetic feedback (GF) plus standard behavioral counseling (BC) for smoking cessation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard behavioral counseling (BC) without genetic feedback (GF)
Number of subjects: 36
Study: 20580572

Group type: EXPERIMENTAL
Intervention: Isoflurane (inspired concentration between 1.0% and 2.5%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propofol (1.5 to 3.5 mg/kg/h)
Number of subjects: 45
Study: 18167121

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) 5 x 10(9) colony-forming units twice daily for 4-6 weeks before delivery and 6 months post-natal
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: In vitro stimulation with LGG
Number of subjects: 68

Group type: COMPARATOR
Intervention: Maternal and neonatal mononuclear cells (MC)
Number of subjects: 68
Study: 16490395

Group type: EXPERIMENTAL
Intervention: Endurance-strength training regime for the cervical flexor muscles
Number of subjects: 58

Group type: COMPARATOR
Intervention: Referent exercise intervention involving low load retraining of the cranio-cervical flexor muscles
Number of subjects: 58
Study: 12623165

Group type: EXPERIMENTAL
Intervention: Gliclazide (10 microg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gliclazide (5-10 microg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0
Study: 10688717

Group type: EXPERIMENTAL
Intervention: 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin solution (Solagé)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.01% tretinoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 9611297

Group type: EXPERIMENTAL
Intervention: Lactose-containing formula (Ninho 10%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactose-free formula (Portagen)
Number of subjects: 40
Study: 8456784

Group type: EXPERIMENTAL
Intervention: Debonding with orthodontic pliers and enamel clean-up with finishing burs and polishing disks (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Debonding with orthodontic pliers and ultrasonic clean-up of the enamel surface (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasonic debonding enamel clean-up (group 3)
Number of subjects: 30
Study: 3941214

Group type: EXPERIMENTAL
Intervention: Circuit weight training (substituted for volleyball)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (regular exercise: walk/jog and volleyball)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Circuit weight training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (regular exercise)
Number of subjects: 40
Study: 29368537

Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF) regimen (elvitegravir, cobicistat, emtricitabine, TAF)
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF) regimen
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF) regimen
Number of subjects: 1436
Study: 26905574

Group type: EXPERIMENTAL
Intervention: Preemptive etoricoxib 120 mg and intraabdominal pressure of 7 mmHg
Number of subjects: 120
Study: 24814438

Group type: EXPERIMENTAL
Intervention: Midwife assisted ultrasound guided embryo transfer (ET)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Doctor assisted ultrasound guided embryo transfer (ET)
Number of subjects: 553
Study: 22840917

Group type: EXPERIMENTAL
Intervention: Extended-release niacin 2 g
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20528801

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Flavoured water (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BCAA supplementation and resistance exercise
Number of subjects: 9
Study: 18538913

Group type: EXPERIMENTAL
Intervention: Calcium silicate paste based on Portland cement (DSC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: D/Sense Crystal (oxalate-based product)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: By Sealant (oxalate-based product)
Number of subjects: 4

Group type: COMPARATOR
Intervention: GC Tooth Mousse (commercial re-mineralizing treatment)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Dentosan S (commercial toothpaste)
Number of subjects: 4
Study: 16612708

Group type: EXPERIMENTAL
Intervention: Vasopressin injections (10 pmol/kg bw)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10704629

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FD patients
Number of subjects: 0
Study: 9087480

Group type: EXPERIMENTAL
Intervention: Cefdinir, 7 mg/kg of body weight twice a day for 10 days
Number of subjects: 394

Group type: COMPARATOR
Intervention: Cephalexin, 10 mg/kg four times a day for 10 days
Number of subjects: 394
Study: 8384645

Group type: EXPERIMENTAL
Intervention: Angiotensin II (5 ng/kg per min) infusion for 60 minutes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Enalaprilat (1 mg intravenously) administration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle control infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle control administration
Number of subjects: 22
Study: 3739804

Group type: EXPERIMENTAL
Intervention: Response-contingent tone and puff
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 3

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 3
Study: 31585546

Group type: EXPERIMENTAL
Intervention: Overall neonatal sepsis
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Early-onset sepsis
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Late-onset sepsis
Number of subjects: 504
Study: 28399799

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg (Group S)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sugammadex 2 mg/kg with neostigmine 50 μg/kg (Group NS)
Number of subjects: 56
Study: 26113439

Group type: EXPERIMENTAL
Intervention: ITF enriched breads (12% fructooligosaccharides and 12% inulin)
Number of subjects: 11
Study: 23073720

Group type: EXPERIMENTAL
Intervention: Internally driven blink (participants were cued to blink their eyes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Externally driven blink (offsetting and then onsetting the preview)
Number of subjects: 0
Study: 21907536

Group type: EXPERIMENTAL
Intervention: Microincision hydrophilic intraocular lens (Idea 613 XC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard hydrophobic open-loop acrylic IOL (Acrysof SA60AT)
Number of subjects: 35
Study: 19165436

Group type: EXPERIMENTAL
Intervention: Standard Conservative Treatment (SCT)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: SCT and tendon and nerve gliding exercises
Number of subjects: 111

Group type: COMPARATOR
Intervention: Tendon and nerve gliding exercises only
Number of subjects: 111
Study: 16442888

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 63795

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 63795

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63795

Group type: EXPERIMENTAL
Intervention: Pravastatin, Simvastatin, Atorvastatin
Number of subjects: 63795
Study: 15534165

Group type: EXPERIMENTAL
Intervention: Fluviral S/F (Shire Biologics)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Vaxigrip (Aventis Pasteur)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 11309019

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 49

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane
Number of subjects: 49